Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and India. Analysts predict a nearly 8% YoY growth in consolidated net profit to Rs 2,329 crore. Consolidated revenue is estimated to rise 9% YoY to Rs 12,265.40 crore.
Consolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. Indias largest pharmaceutical company by market capitalization is scheduled to release its earnings on Thursday.